NDA 203858/S-023

SUPPLEMENT APPROVAL

Amryt Pharmaceuticals, Inc.
US Agent for Amryt Pharmaceutical DAC
Attention: Karla Werre
REMS Manager
160 Federal Street, 21st floor
Boston, MA 02110

Dear Ms. Werre:

Please refer to your supplemental new drug application (sNDA) dated and received August 5, 2021, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Juxtapid (lomitapide) capsules.

This Prior Approval sNDA provides for proposed modifications to the approved Juxtapid (lomitapide) risk evaluation and mitigation strategy (REMS).

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter.

RISK EVALUATION AND MITIGATION STRATEGY (REMS) REQUIREMENTS

The REMS for Juxtapid (lomitapide) was originally approved on December 21, 2012, and the most recent REMS modification was approved on May 27, 2021. The REMS consists of elements to assure safe use, an implementation system, and a timetable for submission of assessments of the REMS.

Your proposed modifications to the REMS consist of:

1. Updating the format of the REMS document in line with the recommendations in the *Format and Content of a REMS Document- Guidance for Industry*[1]

2. Changes to program materials secondary to findings of the completed Qualitative Research (QR) around the deficit of prescriber knowledge on program requirements around liver monitoring as demonstrated in recent poor KAB survey scores

[1] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

3. Omitting obsolete materials (2017 Stakeholder letters) and

4. Editorial changes such as added demographic fields to Patient Guide, Patient Prescriber Acknowledgement Form (PPAF) and Prescription Authorization Form (PAF) and other editorial revisions related to punctuation, grammar, spelling, defining acronyms, flow, font, simplification, and consistency to REMS appended materials.

Your proposed modified REMS, submitted on August 5, 2021, amended and appended to this letter, is approved.

The timetable for submission of assessments of the REMS must be revised. Submit REMS assessments every two years beginning with the 11-year REMS assessment due December 21, 2023.

The revised REMS assessment plan must include, but is not limited to, the following:

Program Implementation and Operations (per reporting period and cumulatively)

1. REMS Enrollment Statistics
    a. Healthcare Provider Certification
        i. The number of newly certified healthcare providers and the number of active healthcare providers (prescribed at least once during the reporting period) in the Juxtapid REMS Program stratified by healthcare provider credentials (e.g., Doctor of Medicine, Doctor of Osteopathic Medicine, Nurse Practitioner, Physician Assistant) and specialty (cardiology, endocrinology, internal medicine, other (and include a full breakdown of prescribing specialties contained in the "other" category)), and practice type (e.g., individual practice, group practice, hospital, university (academic) center), and geographic region (as defined by US Census).
        ii. Method of certification (i.e. through fax, or email).
    b. Pharmacy Enrollment
        i. The number of pharmacies that were newly certified and the number of pharmacies that were active (dispensed Juxtapid at least once during the reporting period) in the REMS program, stratified by geographic region (as defined by US Census)
        ii. Method of certification (e.g., through fax, or email).
    c. Wholesaler/Distributor Authorization
        i. The number of wholesalers/distributors that were newly authorized in the REMS program and the number that were active (shipped Juxtapid at least once during the reporting period).

2. REMS Compliance

   a. Provide a summary of non-compliance identified, including but not limited to:

      i. Provide a copy of the non-compliance plan used during that reporting period, including the criteria for non-compliance for each stakeholder, actions taken to address non-compliance for each case, and which events lead to de-certification from the REMS

      ii. Detailed description of root cause of noncompliance with REMS program required dispensing and any corrective and/or preventive actions taken to address noncompliance during the reporting period and cumulatively.

      iii. Provide a copy of the audit plan for each stakeholder (i.e. certified pharmacies, wholesalers/distributors, or other entities) including any auditing surveys or protocols used

      iv. Report of audit findings for each stakeholder

         1. The number of audits expected, and the number of audits conducted

         2. The number and types of deficiencies noted for each group of audited stakeholders

         3. For those with deficiencies noted, report the number that successfully completed a corrective and preventive action (CAPA) within one month of audit

         4. Include a unique ID for each stakeholder that had deviations to track deviations by stakeholder over time

   b. Healthcare Provider

      i. Number of healthcare providers who that had their certification revoked during the reporting period and cumulatively and the reason for the revocation

      ii. Information on the number of prescribers who have submitted an altered Juxtapid REMS Program Prescription Authorization Form (and what alterations were made).

   c. Pharmacies

      i. Number of pharmacies that had their certification revoked during the reporting period and cumulatively and the reason for the revocation.

      ii. The number of instances certified pharmacies dispensed Juxtapid using a prescription that was not accompanied by a Juxtapid REMS

Program Patient-Prescriber Acknowledgement Form.

iii. Number of instances certified pharmacies dispensed Juxtapid in response to a prescription received on an altered Juxtapid REMS Program Prescription Authorization Form.

iv. The number of new prescriptions received, and the number that were not accompanied by the Juxtapid REMS Program Prescription Authorization Form.

d. Wholesalers/Distributors

i. Number of wholesalers/distributors that had their authorization revoked during the reporting period and cumulatively and the reason for the revocation.

ii. Number of Juxtapid orders shipped to non-certified pharmacies.

3. REMS Call Center

a. Summary of issues and complaints received by Juxtapid REMS Program Call Center; summary of resolution of the issues and complaints.

b. Summary of the reasons (and numbers per reason) for calls into the Juxtapid REMS Program Call Center.

4. Juxtapid Utilization Data

a. The number of prescriptions dispensed for Juxtapid, including quantity of capsules (mean, minimum, maximum) and dosage strength, overall and subset by compliance with the Juxtapid REMS Program requirements (e.g., received from Juxtapid certified vs. non-certified healthcare providers, number of initial prescriptions dispensed without a signed attestation on the Juxtapid REMS Program Prescription Authorization Form). Dispensing details are to be obtained from the pharmacies.

b. Volume of prescriptions for each prescriber stratified by specialty, including a full breakdown of prescribing specialties contained in the “other” category.

c. Specialties of the “high volume” prescribers, i.e., those who write more than four prescriptions in an assessment period and cumulatively, including a full breakdown of prescribing specialties contained in the “other” category.

d. The number of Juxtapid orders shipped to pharmacies during the reporting period and cumulatively, including number of bottles, bottle size and dosage strength.

e. The number and demographics (e.g., including gender, age, geographic location) of unique patients who received Juxtapid during the reporting period

and annually. The number is to be calculated by reconciling orders dispensed to unique patients.

f. Duration of therapy for patients (mean, median, range).

g. The number of prescriptions pending and canceled, as well as the reason for prescriptions pending and canceled.

h. Specific criterion used to classify a prescription as canceled.

i. Report of number, length, and reasons for shipment delays to patients and whether or not these reasons were related to the REMS, and any additional information from insurance payers as to what they are stating as the reason for delay/non-payment.

j. Percentage of fill delays that involve new prescriptions versus refills.

Knowledge (per reporting period and cumulatively)

5. Knowledge, Attitudes, and Behavior (KAB) Surveys of Prescribers to assess understanding of:
    a. The approved indication of Juxtapid
    b. The risk of hepatoxicity associated with Juxtapid use
    c. The need to monitor patients during treatment with Juxtapid as per product labeling
6. Survey to Evaluate Patient Knowledge of:
    a. the risk of hepatoxicity
    b. the need for baseline and periodic monitoring
7. Specification of measures that would be taken to increase awareness if surveys indicate that awareness of the risks associated to Juxtapid is not adequate.

Safe Use Conditions (per reporting period and cumulatively)

8. Prescription Authorization Form (PAF)
    a. Number of patients with completed PAFs who have not received a dispensed prescription for Juxtapid.
    b. Time between receipt of PAF and prescription dispensing and analysis and summary of reasons for delays
    c. Proportion of prescriptions that were associated with the updated PAF from the February 2022 REMS modification.
9. Patient-Prescriber Acknowledgement Form (PPAF)
    a. Proportion of dispensed prescriptions associated with an updated PPAF from

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.